Intranasal Erythropoietin Protects CA1 Hippocampal Cells, Modulated by Specific Time Pattern Molecular Changes After...

Area of Science:

• Neuroscience
• Pharmacology
• Cellular Biology

Background:

• Erythropoietin (EPO) is a molecule with known neuroprotective effects, particularly against cerebral ischemia.
• Optimal administration pathways and dosages for EPO's neuroprotective effects remain underexplored.

Purpose of the Study:

• To investigate the neuroprotective effects of different intranasal doses of recombinant human EPO (rHuEPO) on the CA1 hippocampal region following ischemic damage.
• To determine the most effective timing and dosage of rHuEPO for mitigating ischemic cellular damage.
• To analyze changes in gene and protein expression of EPO, EPO receptor (EPOR), and beta common receptor (βcR) following rHuEPO treatment.

Main Methods:

• Rats were subjected to an ischemia model, and different intranasal doses of rHuEPO (500, 1000, 2500 IU/kg) were administered at 1, 6, and 24 hours post-injury.
• Histopathological analysis of the CA1 region was performed to assess neuronal damage.
• Gene and protein expression levels of EPO, EPOR, and βcR were evaluated in the most effective treatment group.

Main Results:

• Intranasal rHuEPO administration demonstrated protective effects against ischemic cellular damage in the CA1 region.
• The 1000 IU/kg dose of rHuEPO showed significant neuroprotection, particularly when administered 1 hour post-injury.
• Gene expression of EPO and EPOR was upregulated at 1 hour post-treatment, while βcR was upregulated in ischemic and treated groups.
• Protein expression showed no significant change in EPO but a tendency to increase at 24 hours; EPOR was significantly upregulated from 6 to 24 hours post-treatment.

Conclusions:

• A single intranasal dose of rHuEPO, specifically 1000 IU/kg administered 1 hour post-ischemic injury, promotes histological neurorestoration in the CA1 hippocampal region.
• While not strictly dose-dependent, the medium dose of 1000 IU/kg was most effective.
• rHuEPO treatment induces molecular changes, including altered gene and protein expression of EPO, EPOR, and βcR, providing a basis for its neuroprotective platform.